A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma 2023 Feb;64(2):473-477
Date
12/16/2022Pubmed ID
36517990Pubmed Central ID
PMC10652187DOI
10.1080/10428194.2022.2148212Scopus ID
2-s2.0-85144130323 (requires institutional sign-in at Scopus site) 2 CitationsAuthor List
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HPAuthor
Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AzacitidineHumans
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Middle Aged
Myelodysplastic Syndromes
